on MEDIAN TECHNOLOGIES (EPA:ALMDT)
Median Technologies and AI in lung cancer screening
On November 7, 2024, Median Technologies will host a web conference on the impact of Artificial Intelligence in lung cancer screening. This event will focus on the results of the REALITY study of their eyonis™ LCS medical device software.
Key opinion leaders such as Professor Anil Vachani and Professor Javier Zulueta will discuss the importance of these new data. CEO Fredrik Brag will present the results, which will be submitted for marketing authorization in the US and Europe in 2025.
Discussions will focus on the ability of eyonis™ LCS to improve early diagnosis. This could increase the detection rate of cancers at an early stage, thereby increasing the potential for cure for patients.
R. P.
Copyright © 2024 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all MEDIAN TECHNOLOGIES news